Abstract
Resistance to undergo apoptosis is a characteristic feature of human malignancies, including childhood leukemia. Apoptosis, or programmed cell death, is the most common intrinsic cell death programs that plays a critical role in maintaining tissue homeostasis, for example in the hematopoietic system. Accordingly, too little apoptosis can promote tumor formation and also treatment resistance, since the anti-leukemic activity of most current treatment approaches, i.e. chemo-, radio- or immunotherapy critically depends on intact apoptosis signaling pathways in leukemia cells. Thus, defective apoptosis programs confer resistance to anti-leukemic therapy. The elucidation of the signaling components mediating apoptosis in leukemia cells has provided multiple targets for therapeutic intervention. These targets can be exploited to develop novel treatment strategies better directed at selective intervention points in the apoptotic machinery. Several of these approaches have already been translated into a clinical application. Thus, the exploitation of apoptosis signaling pathways for leukemia therapy opens new perspectives for effective treatment protocols for childhood leukemia.
Keywords: Apoptosis, leukemia, TRAIL, IAPs, mitochondria, Signaling pathways, Bcl-2 PROTEINS, Receptor, Caspase, Bcl-2 inhibitors
Current Pediatric Reviews
Title: Exploitation of Apoptosis Pathways for Childhood Leukemia
Volume: 7 Issue: 4
Author(s): Simone Fulda
Affiliation:
Keywords: Apoptosis, leukemia, TRAIL, IAPs, mitochondria, Signaling pathways, Bcl-2 PROTEINS, Receptor, Caspase, Bcl-2 inhibitors
Abstract: Resistance to undergo apoptosis is a characteristic feature of human malignancies, including childhood leukemia. Apoptosis, or programmed cell death, is the most common intrinsic cell death programs that plays a critical role in maintaining tissue homeostasis, for example in the hematopoietic system. Accordingly, too little apoptosis can promote tumor formation and also treatment resistance, since the anti-leukemic activity of most current treatment approaches, i.e. chemo-, radio- or immunotherapy critically depends on intact apoptosis signaling pathways in leukemia cells. Thus, defective apoptosis programs confer resistance to anti-leukemic therapy. The elucidation of the signaling components mediating apoptosis in leukemia cells has provided multiple targets for therapeutic intervention. These targets can be exploited to develop novel treatment strategies better directed at selective intervention points in the apoptotic machinery. Several of these approaches have already been translated into a clinical application. Thus, the exploitation of apoptosis signaling pathways for leukemia therapy opens new perspectives for effective treatment protocols for childhood leukemia.
Export Options
About this article
Cite this article as:
Fulda Simone, Exploitation of Apoptosis Pathways for Childhood Leukemia, Current Pediatric Reviews 2011; 7(4) . https://dx.doi.org/10.2174/157339611796892355
DOI https://dx.doi.org/10.2174/157339611796892355 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Immunomodulatory Therapy Associated to Anti-Parasite Drugs as a Way to Prevent Severe Forms of Malaria
Current Clinical Pharmacology Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Current Medicinal Chemistry Voltage-Gated Sodium Channels as Therapeutic Targets for Treatment of Painful Diabetic Neuropathy
Mini-Reviews in Medicinal Chemistry Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology Inflammatory Bowel Disease and Celiac Disease: Overlaps in the Pathology and Genetics, and their Potential Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets Assessment of Adverse Drug Reaction Due to Cancer Chemotherapy in a Teaching Oncology Hospital in Isfahan, Central of Iran
Reviews on Recent Clinical Trials The Nutrigenetics and Pharmacogenetics of Vitamin D Pathways
Current Pharmacogenomics and Personalized Medicine Late Effects in Survivors of Childhood CNS Tumors: Review of Results From the Two Largest Survivorship Cooperative Groups
Current Cancer Therapy Reviews Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
Current Pharmaceutical Design Ferroquine: A New Weapon in the Fight Against Malaria
Current Medicinal Chemistry - Anti-Infective Agents The Use of Radioactive Iodine in the Management of Hyperthyroidism in Children
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Adolescents Attitudes Toward Vaccinations: A Systematic Review
Current Pediatric Reviews Zinc and Copper Homeostasis in Head and Neck Cancer: Review and Meta-Analysis
Current Medicinal Chemistry Marine Metabolites Overcoming or Circumventing Multidrug Resistance Mediated by ATP-Dependent Transporters: A New Hope for Patient with Tumors Resistant to Conventional Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Application of Genetic Polymorphisms in DNA Repair in the Prediction of Cancer Susceptibility and Clinical Outcome
Current Pharmacogenomics Histone Acetylation in Neurodevelopment
Current Pharmaceutical Design